BioSpace News Archive

Nu-Med Plus’s Proprietary Technology is designed to open new patient markets by providing treatment options in remote and rural areas with a unique product for the generation of Nitric Oxide that has the capability to rapidly deliver the gas when serious and instantaneous use is needed.

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA molecules in metabolic diseases.

AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications.

Incyte announced the validation of the Company’s Marketing Authorization Application for pemigatinib for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy.

Alzheon, Inc. announced that Christopher Noel Dunn, Jordan Heller, and Diane K. Jorkasky, MD, FACP, have been appointed to the company’s board of directors.

TherapeuticsMD, Inc. and PlushCare announced that TherapeuticsMD’s women’s health products can be prescribed to patients via the PlushCare platform.

Co-Diagnostics, Inc. announced that the Company’s groundbreaking Co-Diagnostics CoPrimer™ technology will be featured at the International Plant & Animal Genome XXVIII conference, held on January 11-15 in San Diego, CA.

CureVac AG announced positive data from an interim analysis of safety and immunogenicity in its Phase 1 study evaluating CV7202, a novel prophylactic mRNA-based rabies vaccine.

Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company’s Prior Revenue Guidance

Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024